Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
The two companies will work together for the Prospective Evaluation of OrionAI – a revolutionary AI-based Diagnostic Assistant for Histological Examination of a variety of solid tumours beginning with Head and Neck Squamous Cell Carcinoma (HNSCC) Cancer
Subscribe To Our Newsletter & Stay Updated
